<DOC>
	<DOCNO>NCT01143662</DOCNO>
	<brief_summary>This study multi-center , randomize , open-label positive control Phase II Clinical trial ass efficacy safety Ypeginterferon alfa-2b , week , 3 dose-groups : 90mcg , 135mcg 180mcg , respectively , treatment chronic hepatitis B characterize HBeAg positivity , Pegasys 180mcg/week positive control . It aim establish dose response safety relationship sufficient allow subsequent design conduct Phase III trial , generate pharmacokinetic data Ypeginterferon alfa-2b hepatitis B patient satisfy regulatory requirement .</brief_summary>
	<brief_title>Efficacy Safety Ypeginterferon Alfa-2b HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age:18~60 year . Pregnancy test female patient must negative . All patient effective birth control measure treatment period 6 month cessation treatment . Serum HBsAg positive least 6 month . Serum HBeAg positive HBV DNA ≥20,000IU/ml . 2×ULN≤ALT≤10×ULN screening ( ULN=upper limit normal ) . Pregnant lactating woman . Mental disorder physical disability . Interferon treatment history use nucleos ( ) ide analogue chronic hepatitis B treatment within previous 6 month . WBC &lt; 3000/mm3 , ANC &lt; 1500/mm3 , PLT &lt; 90,000/mm3 . Coinfection HAV , HIV , HCV , HDV , HEV . Both HBsAg antiHBs positive , HBeAg antiHBe positive screening . Chest Xray clinically significant active inflammatory process , history significant pulmonary disease history interstitial lung disease . Evidence hepatic decompensation . History hypothyroidism current treatment thyroid disease . Uncontrolled significant chronic medical condition chronic hepatitis B , condition opinion investigator preclude enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>peginterferon</keyword>
	<keyword>interferon</keyword>
	<keyword>Pegasys</keyword>
	<keyword>HBV</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
</DOC>